The fracturing of the US drug market’s traditional model is forcing a demand for a strategic bifurcation to maintain profitability, compliance, and patient access in the decade ahead. Building on my ...

A fixed 15.5% manufacturer rebate on patented branded drugs replaces a proposed variable, expenditure-linked mechanism after coordinated industry pressure and threats to curtail German investment and ...

PBM reform scrutiny of reimbursement, rebate flow, and compensation can shift benefit conditions that determine how manufacturer-funded copay, buy-down, and support programs function at dispensing.

Pairing Tennr referral intake and documentation automation with TailorMed affordability tooling is designed to surface access barriers earlier and shorten time-to-therapy for infusion and specialty ...

CMS-driven price relief may expand access, but adherence is the key determinant of durable cardiometabolic and weight outcomes in chronic-disease management. Discontinuation rates are high: roughly ...

Dual BAFF/APRIL blockade targets upstream B-cell survival signaling to reduce production of galactose-deficient IgA1 and anti–Gd-IgA1 autoantibodies driving nephritogenic immune complexes. ORIGIN 3 ...

CoT operationalizes channel behavior into system rules that determine customer-specific pricing tiers, discounts, rebates, and distribution pathways, particularly for specialty medicines routed ...

Section 232 introduces a staged tariff regime: 100% default for patented drugs/APIs/KSMs, reduced 20% with approved onshoring plans, and temporary 0% if paired with MFN pricing until 2029. Deadlines ...

Medication nonadherence is common and costly, with higher rates in biologics for autoimmune disease (28–52%), reflecting intertwined barriers spanning beliefs, side effects, affordability, and ...

Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, explains which therapeutic areas will lead DTP adoption and her five-year outlook for the model. Direct-to-patient (DTP) programs are no ...